FLOW Trial Shows Benefit of Semaglutide in Type 2 Diabetes and CKD: EASD 2024
Findings from the FLOW trial, the first dedicated kidney outcomes trial with semaglutide in patients with Type 2 diabetes and chronic kidney disease, were presented at EASD 2024.